peripheral t-cell lymphoma in 2013
DESCRIPTION
Peripheral T-Cell Lymphoma in 2013. Program Goal. WHO 2008 Classification of Mature T/NK-Cell Neoplasms. Use of the Term PTCL. PTCL, PTCL Mature (Post-Thymic) T-Cell Lymphomas. International PTCL Study: Major NHL Types by Region. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/1.jpg)
Peripheral T-Cell Lymphoma in 2013
![Page 2: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/2.jpg)
Program Goal
![Page 3: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/3.jpg)
WHO 2008 Classification of Mature T/NK-Cell Neoplasms
![Page 4: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/4.jpg)
Use of the Term PTCL
![Page 5: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/5.jpg)
PTCL, PTCL Mature (Post-Thymic) T-Cell Lymphomas
![Page 6: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/6.jpg)
International PTCL Study: Major NHL Types by Region
![Page 7: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/7.jpg)
Key Points in the Pathology Characteristics of the Most Common Subtypes of PTCL
![Page 8: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/8.jpg)
ALK and ALCL
![Page 9: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/9.jpg)
Outcomes by PTCL Subtypes
![Page 10: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/10.jpg)
Prognostic Indices for PTCL
![Page 11: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/11.jpg)
Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Results of a
Prospective Multicenter Study
![Page 12: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/12.jpg)
CHOP: First-line Treatment of PTCL
![Page 13: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/13.jpg)
Alemtuzumab (A) + Chemotherapy
First-line treatment of PTCL
![Page 14: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/14.jpg)
CHOP+ and Non-CHOP: First-line Treatment of PTCL
![Page 15: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/15.jpg)
Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-Free
Survival of Younger Patients
![Page 16: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/16.jpg)
Treatment and Prognosis of Mature T-Cell and NK-Cell Lymphoma: Event-free Survival
of Younger Patients (cont)
![Page 17: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/17.jpg)
Autologous Stem Cell Transplantation as First-line Therapy in PTCL: Survival
![Page 18: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/18.jpg)
Prognostic Factors in Trials of ASCT in First Remission
![Page 19: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/19.jpg)
ICE and Planned ASCT for Relapsed/Refractory T-Cell Lymphoma: PFS From ICE
![Page 20: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/20.jpg)
CIBMTR Auto and Allo for PTCL: Outcomes Excluding Patients in
CR1
![Page 21: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/21.jpg)
Retrospective Analyses of Allogeneic Stem-Cell
Transplantation for PTCL
![Page 22: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/22.jpg)
Approved Agents in Relapsed/Refractory PTCL
![Page 23: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/23.jpg)
PROPEL: Adverse Events ≥ Gr 3 Occurring in ≥ 3% of Patients
(n = 111)
![Page 24: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/24.jpg)
Treatment-related Adverse Events With Romidepsin in ≥ 20% of Patients (N = 131)
![Page 25: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/25.jpg)
Brentuximab Vedotin: Phase 2 Study in Relapsed/Refractory Systemic ALCL
![Page 26: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/26.jpg)
Brentuximab Vedotin in Relapsed ALCL: Toxicities
![Page 27: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/27.jpg)
Brentuximab: Best Clinical Response by Disease
Diagnosis
![Page 28: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/28.jpg)
Brentuximab: Maximum Tumor Volume Reduction by Frequency of CD30+ Cells
![Page 29: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/29.jpg)
Front-line Therapy: Study Design (Combination Therapy
Arms)
![Page 30: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/30.jpg)
Front-line Therapy: Best Response by Disease
Diagnosis
![Page 31: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/31.jpg)
Bendamustine in T-Cell Lymphoma (BENTLY Trial)
![Page 32: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/32.jpg)
Lenalidomide in Relapsed/Refractory TCL: Phase 2
Trial
![Page 33: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/33.jpg)
Belinostat: PTCL Response Assessed by Central Review
![Page 34: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/34.jpg)
Belinostat: Response Rate by CPRG Lymphoma Diagnosis
![Page 35: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/35.jpg)
Belinostat: Grade ≥3 Nonhematologic AEs in Patients With R/R PTCL (N=120)
![Page 36: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/36.jpg)
MLN8237: Response (PR + CR) by Histology
![Page 37: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/37.jpg)
IPI-145: A PI3K-δ,γ Inhibitor
![Page 38: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/38.jpg)
Early Signs of Clinical Activity of IPI-145 in T-Cell Lymphoma
![Page 39: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/39.jpg)
Mogamulizumab (KW-0761)Anti-CCR4 Monoclonal Antibody
![Page 40: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/40.jpg)
Recommended Approach to Patients With Relapsed PTCL (NOS, AITL, ALCL)
![Page 41: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/41.jpg)
Abbreviations
![Page 42: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/42.jpg)
Abbreviations (cont)
![Page 43: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/43.jpg)
Abbreviations (cont)
![Page 44: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/44.jpg)
Abbreviations (cont)
![Page 45: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/45.jpg)
References
![Page 46: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/46.jpg)
References (cont)
![Page 47: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/47.jpg)
References (cont)
![Page 48: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/48.jpg)
References (cont)
![Page 49: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/49.jpg)
References (cont)
![Page 50: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/50.jpg)
References (cont)
![Page 51: Peripheral T-Cell Lymphoma in 2013](https://reader035.vdocuments.net/reader035/viewer/2022062305/56816168550346895dd0f390/html5/thumbnails/51.jpg)
References (cont)